Skip to main page content
Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

MyNCBI Filters
Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
1926 1
1949 1
1953 1
1955 1
1956 2
1960 1
1962 1
1963 1
1964 2
1965 3
1966 2
1967 2
1968 8
1969 5
1970 4
1971 8
1972 6
1973 10
1974 9
1975 14
1976 14
1977 4
1978 4
1979 14
1980 7
1981 11
1982 13
1983 16
1984 14
1985 31
1986 30
1987 27
1988 22
1989 44
1990 41
1991 40
1992 41
1993 42
1994 46
1995 47
1996 62
1997 79
1998 93
1999 92
2000 102
2001 124
2002 120
2003 108
2004 146
2005 133
2006 108
2007 126
2008 132
2009 126
2010 154
2011 162
2012 206
2013 204
2014 179
2015 189
2016 205
2017 194
2018 199
2019 207
2020 70
Text availability
Article attribute
Article type
Publication date

Search Results

3,790 results
Results by year
Filters applied: . Clear all
Page 1
Cabozantinib in Patients with Advanced and Progressing Hepatocellular Carcinoma.
Abou-Alfa GK, Meyer T, Cheng AL, El-Khoueiry AB, Rimassa L, Ryoo BY, Cicin I, Merle P, Chen Y, Park JW, Blanc JF, Bolondi L, Klümpen HJ, Chan SL, Zagonel V, Pressiani T, Ryu MH, Venook AP, Hessel C, Borgman-Hagey AE, Schwab G, Kelley RK. Abou-Alfa GK, et al. Among authors: Meyer T. N Engl J Med. 2018 Jul 5;379(1):54-63. doi: 10.1056/NEJMoa1717002. N Engl J Med. 2018. PMID: 29972759 Free article. Clinical Trial.
An intrinsic S/G2 checkpoint enforced by ATR.
Saldivar JC, Hamperl S, Bocek MJ, Chung M, Bass TE, Cisneros-Soberanis F, Samejima K, Xie L, Paulson JR, Earnshaw WC, Cortez D, Meyer T, Cimprich KA. Saldivar JC, et al. Among authors: Meyer T. Science. 2018 Aug 24;361(6404):806-810. doi: 10.1126/science.aap9346. Science. 2018. PMID: 30139873 Free PMC article.
Nivolumab in patients with advanced hepatocellular carcinoma (CheckMate 040): an open-label, non-comparative, phase 1/2 dose escalation and expansion trial.
El-Khoueiry AB, Sangro B, Yau T, Crocenzi TS, Kudo M, Hsu C, Kim TY, Choo SP, Trojan J, Welling TH Rd, Meyer T, Kang YK, Yeo W, Chopra A, Anderson J, Dela Cruz C, Lang L, Neely J, Tang H, Dastani HB, Melero I. El-Khoueiry AB, et al. Among authors: Meyer T. Lancet. 2017 Jun 24;389(10088):2492-2502. doi: 10.1016/S0140-6736(17)31046-2. Epub 2017 Apr 20. Lancet. 2017. PMID: 28434648 Clinical Trial.
The outcomes of hypoglossal nerve stimulation in the management of OSA: A systematic review and meta-analysis.
Kompelli AR, Ni JS, Nguyen SA, Lentsch EJ, Neskey DM, Meyer TA. Kompelli AR, et al. Among authors: Meyer TA. World J Otorhinolaryngol Head Neck Surg. 2018 Sep 25;5(1):41-48. doi: 10.1016/j.wjorl.2018.04.006. eCollection 2019 Mar. World J Otorhinolaryngol Head Neck Surg. 2018. PMID: 30775701 Free PMC article. Review.
Comparison of adjuvant gemcitabine and capecitabine with gemcitabine monotherapy in patients with resected pancreatic cancer (ESPAC-4): a multicentre, open-label, randomised, phase 3 trial.
Neoptolemos JP, Palmer DH, Ghaneh P, Psarelli EE, Valle JW, Halloran CM, Faluyi O, O'Reilly DA, Cunningham D, Wadsley J, Darby S, Meyer T, Gillmore R, Anthoney A, Lind P, Glimelius B, Falk S, Izbicki JR, Middleton GW, Cummins S, Ross PJ, Wasan H, McDonald A, Crosby T, Ma YT, Patel K, Sherriff D, Soomal R, Borg D, Sothi S, Hammel P, Hackert T, Jackson R, Büchler MW; European Study Group for Pancreatic Cancer. Neoptolemos JP, et al. Among authors: Meyer T. Lancet. 2017 Mar 11;389(10073):1011-1024. doi: 10.1016/S0140-6736(16)32409-6. Epub 2017 Jan 25. Lancet. 2017. PMID: 28129987 Free article. Clinical Trial.
July 2017 ENCALS statement on edaravone.
Al-Chalabi A, Andersen PM, Chandran S, Chio A, Corcia P, Couratier P, Danielsson O, de Carvalho M, Desnuelle C, Grehl T, Grosskreutz J, Holmøy T, Ingre C, Karlsborg M, Kleveland G, Koch JC, Koritnik B, KuzmaKozakiewicz M, Laaksovirta H, Ludolph A, McDermott C, Meyer T, Mitre Ropero B, Mora Pardina J, Nygren I, Petri S, Povedano Panades M, Salachas F, Shaw P, Silani V, Staaf G, Svenstrup K, Talbot K, Tysnes OB, Van Damme P, van der Kooi A, Weber M, Weydt P, Wolf J, Hardiman O, van den Berg LH. Al-Chalabi A, et al. Among authors: Meyer T. Amyotroph Lateral Scler Frontotemporal Degener. 2017 Nov;18(7-8):471-474. doi: 10.1080/21678421.2017.1369125. Epub 2017 Oct 4. Amyotroph Lateral Scler Frontotemporal Degener. 2017. PMID: 28975816 Free article. Review. No abstract available.
Safety and efficacy of rasagiline as an add-on therapy to riluzole in patients with amyotrophic lateral sclerosis: a randomised, double-blind, parallel-group, placebo-controlled, phase 2 trial.
Ludolph AC, Schuster J, Dorst J, Dupuis L, Dreyhaupt J, Weishaupt JH, Kassubek J, Weiland U, Petri S, Meyer T, Grosskreutz J, Schrank B, Boentert M, Emmer A, Hermann A, Zeller D, Prudlo J, Winkler AS, Grehl T, Heneka MT, Wollebæk Johannesen S, Göricke B; RAS-ALS Study Group. Ludolph AC, et al. Among authors: Meyer T. Lancet Neurol. 2018 Aug;17(8):681-688. doi: 10.1016/S1474-4422(18)30176-5. Epub 2018 Jun 19. Lancet Neurol. 2018. PMID: 29934198 Clinical Trial.
The lysosomal GPCR-like protein GPR137B regulates Rag and mTORC1 localization and activity.
Gan L, Seki A, Shen K, Iyer H, Han K, Hayer A, Wollman R, Ge X, Lin JR, Dey G, Talbot WS, Meyer T. Gan L, et al. Among authors: Meyer T. Nat Cell Biol. 2019 May;21(5):614-626. doi: 10.1038/s41556-019-0321-6. Epub 2019 Apr 29. Nat Cell Biol. 2019. PMID: 31036939 Free PMC article.
3,790 results
Jump to page
Feedback